GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Long-Term Debt

Supernus Pharmaceuticals (FRA:S49) Long-Term Debt : €0.0 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Long-Term Debt?

Supernus Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2024 was €0.0 Mil.

Supernus Pharmaceuticals's annual Long-Term Debt declined from Dec. 2021 (€335.6 Mil) to Dec. 2022 (€0.0 Mil) but then stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).

Supernus Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Supernus Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Long-Term Debt Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.65 297.36 335.64 - -

Supernus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Supernus Pharmaceuticals  (FRA:S49) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Supernus Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Long-Term Debt
Comparable Companies
PCRX TARO TLRY ANIP IRWD DCPH AVDL COLL DVAX AMRX ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
SUPN:USA 0LB2:UK
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Website
https://www.supernus.com
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals Headlines

No Headlines